Recombinant SARS-CoV-2 S2 protein (T1027I, V1176F), (P.1), His Tag, 100µg

Background
The ongoing SARS-COV-2 pandemics has sickened 3.7 million people around the world, claiming over 1,000,000 lives. To deal with this global public health crisis, unprecedented efforts are being made to study the virus, SARS-CoV-2. At present, there are 193 new crown vaccine projects registered with the World Health Organization are being developed. To support these studies, ACRO has developed Mouse Anti-SARS-CoV-2 antibody IgG Serologic Assay kit.

Source
Recombinant  SARS-CoV-2 S2 protein (T1027I, V1176F), His Tag (S2N-C52He) is expressed from human 293 cells (HEK293). It contains AA Ser 686 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P/ A892P/ A899P/ A942P/ K986P/ V987P) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein. The T1027I/ V1176F mutations were identified in the SARS-CoV-2 variant (known as P.1) which emerged in Brazil.
Predicted N-terminus: Ser 686

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.9 kDa. The protein migrates as 70-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants"
Cheng, Zheng, Zhang et al
J Mol Model (2023) 29 (4), 109
(2) "Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2"
Phan, Layton, Yu et al
J Immunol (2023)
(3) "Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses"
Silva, Huang, Nguyen et al
Elife (2023) 12
Showing 1-3 of 1155 papers